Arthur Felix1, Pablo Berlanga1, Maud Toulmonde2, Judith Landman-Parker3, Sarah Dumont4, Gilles Vassal1, Marie-Cécile Le Deley5, Nathalie Gaspar1. 1. Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif cedex, France. 2. Medical Oncology Department, Institut Bergonié, Bordeaux, France. 3. Service d'Hématologie et d'Oncologie Pédiatrique, Hôpital Armand Trousseau, Paris, France. 4. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. 5. Direction de la Recherche Clinique et de l'Innovation, Centre Oscar Lambret, Lille, France.
Abstract
BACKGROUND: Optimal Phase-II design to evaluate new therapies in refractory/relapsed Ewing sarcomas (ES) remains imperfectly defined. OBJECTIVES: Recurrent/refractory ES phase-I/II trials analysis to improve trials design. METHODS: Comprehensive review of therapeutic trials registered on five databases (who.int/trialsearch, clinicaltrials.gov, clinicaltrialsregister.eu, e-cancer.fr, and umin.ac.jp) and/or published in PubMed/ASCO/ESMO websites, between 2005 and 2018, using the criterion: (Ewing sarcoma OR bone sarcoma OR sarcoma) AND (Phase-I or Phase-II). RESULTS: The 146 trials identified (77 phase-I/II, 67 phase-II, and 2 phase-II/III) tested targeted (34%), chemo- (23%), immune therapies (19%), or combined therapies (24%). Twenty-three trials were ES specific and 48 had a specific ES stratum. Usually multicentric (88%), few trials were international (30%). Inclusion criteria cover the recurrent ES age range for only 12% of trials and allowed only accrual of measurable diseases (RECIST criteria). Single-arm design was the most frequent (88%) testing mainly single drugs (61%), only 5% were randomized. Primary efficacy outcome was response rate (RR=CR+PR; Complete+Partial response) (n = 116/146; 79%), rarely progression-free or overall survival (16% PFS and 3% OS). H0 and H1 hypotheses were variable (3%-25% and 20%-50%, respectively). The 62 published trials enrolled 827 ES patients. RR was poor (10%; 15 CR=1.7%, 68 PR=8.3%). Stable disease was the best response for 186 patients (25%). Median PFS/OS was of 1.9 (range 1.3-14.7) and 7.6 months (5-30), respectively. Eleven (18%) published trials were considered positive, with median RR/PFS/OS of 15% (7%-30%), 4.5 (1.3-10), and 16.6 months (6.9-30), respectively. CONCLUSION: This review supports the need to develop the international randomized phase-II trials across all age ranges with PFS as primary endpoint.
BACKGROUND: Optimal Phase-II design to evaluate new therapies in refractory/relapsed Ewing sarcomas (ES) remains imperfectly defined. OBJECTIVES: Recurrent/refractory ES phase-I/II trials analysis to improve trials design. METHODS: Comprehensive review of therapeutic trials registered on five databases (who.int/trialsearch, clinicaltrials.gov, clinicaltrialsregister.eu, e-cancer.fr, and umin.ac.jp) and/or published in PubMed/ASCO/ESMO websites, between 2005 and 2018, using the criterion: (Ewing sarcoma OR bone sarcoma OR sarcoma) AND (Phase-I or Phase-II). RESULTS: The 146 trials identified (77 phase-I/II, 67 phase-II, and 2 phase-II/III) tested targeted (34%), chemo- (23%), immune therapies (19%), or combined therapies (24%). Twenty-three trials were ES specific and 48 had a specific ES stratum. Usually multicentric (88%), few trials were international (30%). Inclusion criteria cover the recurrent ES age range for only 12% of trials and allowed only accrual of measurable diseases (RECIST criteria). Single-arm design was the most frequent (88%) testing mainly single drugs (61%), only 5% were randomized. Primary efficacy outcome was response rate (RR=CR+PR; Complete+Partial response) (n = 116/146; 79%), rarely progression-free or overall survival (16% PFS and 3% OS). H0 and H1 hypotheses were variable (3%-25% and 20%-50%, respectively). The 62 published trials enrolled 827 ES patients. RR was poor (10%; 15 CR=1.7%, 68 PR=8.3%). Stable disease was the best response for 186 patients (25%). Median PFS/OS was of 1.9 (range 1.3-14.7) and 7.6 months (5-30), respectively. Eleven (18%) published trials were considered positive, with median RR/PFS/OS of 15% (7%-30%), 4.5 (1.3-10), and 16.6 months (6.9-30), respectively. CONCLUSION: This review supports the need to develop the international randomized phase-II trials across all age ranges with PFS as primary endpoint.
Authors: Catherine De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Hal C Sox; Martin B Van Der Weyden Journal: N Engl J Med Date: 2004-09-08 Impact factor: 91.245
Authors: A Raciborska; K Bilska; K Drabko; E Michalak; R Chaber; M Pogorzała; K Połczyńska; G Sobol; M Wieczorek; K Muszyńska-Rosłan; M Rychlowska-Pruszyńska; C Rodriguez-Galindo; M Dziuk Journal: Clin Transl Oncol Date: 2015-08-07 Impact factor: 3.405
Authors: C A Bellera; N Penel; M Ouali; S Bonvalot; P G Casali; O S Nielsen; M Delannes; S Litière; F Bonnetain; T S Dabakuyo; R S Benjamin; J-Y Blay; B N Bui; F Collin; T F Delaney; F Duffaud; T Filleron; M Fiore; H Gelderblom; S George; R Grimer; P Grosclaude; A Gronchi; R Haas; P Hohenberger; R Issels; A Italiano; V Jooste; A Krarup-Hansen; C Le Péchoux; C Mussi; O Oberlin; S Patel; S Piperno-Neumann; C Raut; I Ray-Coquard; P Rutkowski; S Schuetze; S Sleijfer; E Stoeckle; M Van Glabbeke; P Woll; S Gourgou-Bourgade; S Mathoulin-Pélissier Journal: Ann Oncol Date: 2014-07-28 Impact factor: 32.976
Authors: Robin E Norris; Elizabeth Fox; Joel M Reid; Andrew Ralya; Xiaowei W Liu; Charles Minard; Brenda J Weigel Journal: Pediatr Blood Cancer Date: 2018-01-02 Impact factor: 3.167
Authors: Lara E Davis; Vanessa Bolejack; Christopher W Ryan; Kristen N Ganjoo; Elizabeth T Loggers; Sant Chawla; Mark Agulnik; Michael B Livingston; Damon Reed; Vicky Keedy; Daniel Rushing; Scott Okuno; Denise K Reinke; Richard F Riedel; Steven Attia; Leo Mascarenhas; Robert G Maki Journal: J Clin Oncol Date: 2019-04-23 Impact factor: 44.544
Authors: Denise A Casey; Leonard H Wexler; Melinda S Merchant; Alexander J Chou; Pamela R Merola; Anita P Price; Paul A Meyers Journal: Pediatr Blood Cancer Date: 2009-12 Impact factor: 3.167